Investor Relations

Prime Medicine is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies to address the widest spectrum of diseases by deploying its versatile, precise, effective and broad next generation gene editing technology, Prime Editing. Designed to make only the right edit at the right position within a gene, the Company’s Prime Editing technology has broad therapeutic applications and is capable of repairing approximately 90 percent of known disease-causing mutations across many organisms, organs, and cell types. Prime Medicine has purposefully built a diversified portfolio organized around four strategic indication categories, with each set of indications chosen to deliver a different strategic goal, and is currently advancing a broad portfolio of therapeutic programs.